Skip to main content Accessibility help
×
Home

A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder

  • Alan D. Feiger, Karen A. Tourian, Gregory R. Rosas and S. Krishna Padmanabhan

Abstract

Introduction: This research compares the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) versus placebo in treating major depressive disorder.

Methods: In this randomized, double-blind study, outpatients with major depressive disorder ≥18 years of age received desvenlafaxine 200–400 mg/day or placebo for 8 weeks. Efficacy endpoints included (primary) change in 17-item Hamilton Rating Scale for Depression score at the final evaluation (last observation carried forward, analysis of covariance) and (secondary) Clinical Global Impressions—Improvement and—Severity of Illness scales.

Results: The difference between desvenlafaxine (n=117) and placebo (n=118) on the primary endpoint was not significant (−9.1 vs −7.5, P=.078). Week 8 observed cases (desvenlafaxine, n=80; placebo, n=94) results were significant (−10.7 vs −7.9, P=.008). Differences at the final evaluation (last observation carried forward) were significant for Clinical Global Impressions—Improvement (2.9 vs 2.5, P=.037) and Clinical Global Impressions—Severity of Illness (−1.9 vs −1.2, P=.041). Discontinuation rates due to adverse events (AEs) were 12% and 3% for desvenlafaxine and placebo, respectively (P=.008). The most frequently reported AE associated with desvenlafaxine was nausea (36% vs 9% [placebo]).

Conclusion: In this study, the primary analysis did not show significant differences between desvenlafaxine and placebo; discontinuations due to AEs associated with the desvenlafaxine dose range may have contributed to the lack of statistical separation.

Copyright

Corresponding author

Please direct all correspondence to: Alan D. Feiger, MD, 395 Franklin St, Denver, CO 80218; Tel: 303-425-4298; Fax: 303-425-4303; E-mail: afeiger@rtacolorado.com.

References

Hide All
1.World Health Organization Web site. Depression. Available at: http://www.who.int/mental_health/management/depression/definition/en/print.html. Accessed August 7, 2007.
2.Schatzberg, AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry. 2007;68(suppl 8):2634.
3.Khan, A, Leventhal, RM, Khan, SR, Brown, WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22:4045.
4.Wyeth Pharmaceuticals. Project Listing. Neurosciences and Women's Health and Bone. Available at: http://www.wyeth.com/research/projects. Accessed May 21, 2008.
5. Pristiq [package insert]. Philadelphia, Penn: Wyeth Pharmaceuticals; 2008.
6.Boyer, P, Montgomery, S, Lepola, U, et al.Evaluation of the efficacy and safety of fixed doses of desvenlafaxine succinate at 50 mg and 100 mg in outpatients with major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243253.
7.Liebowitz, M, Manley, AL, Padmanabhan, SK, Ganguly, R, Tummala, R, Tourian, KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24:18771890.
8.DeMartinis, NA, Yeung, PP, Entsuah, R, Manley, AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677688.
9.Septien-Velez, L, Pitrosky, B, Padmanabhan, SK, Germain, J-M, Tourian, KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22:338347.
10.Thase, ME, Kornstein, SG, Yeung, PP, et al. An integrated analysis of the efficacy of desvenlafaxine succinate compared with placebo in the treatment of major depressive disorder. Poster presented at: 47th Annual NCDEU meeting. June 11-14, 2007; Boca Raton, FL.
11.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
12.Hamilton, M. Hamilton Rating Scale for Depression (HAM-D). In: Rush, AJ, Pincus, HA, First, MB, et al, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:526529.
13.Guy, W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Bethesda, Md: US Department of Health, Education and Welfare, National Institute of Mental Health; 1976:217222.
14.Lipman, RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull. 1982;18:6977.
15.Raskin, A. Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis. 1974;159:120130.
16.Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382389.
17.Bech, P. Psychometric developments of the Hamilton Scales: the spectrum of depression, dysthymia, and anxiety. In: Bech, P, Coppen, A, eds. The Hamilton Scales. Berlin, Germany: Springer-Verlag, 1990:7279.
18.The Medical Dictionary for Regulatory Activities. Available at: http://www.meddramsso.com/MSSOWeb/index.htm. Accessed December 11, 2008.
19.Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.
20.Fava, M, Rush, AJ, Trivedi, MH, et al.Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457494.

A Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible-Dose Desvenlafaxine Treatment in Outpatients with Major Depressive Disorder

  • Alan D. Feiger, Karen A. Tourian, Gregory R. Rosas and S. Krishna Padmanabhan

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed